CSF2 and neoplasm: Tregs are one of the most promising candidates and can be selectively depleted administering low doses of cyclophosphamide [149] which, in combination with GVAX, a GM-CSF gene-transfected tumor cell vaccine, showed an enhanced immune response to PDAC [150].